These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37567056)

  • 1. Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.
    Wang P; Zhu WT; Wang Y; Song SS; Xi Y; Yang XY; Shen YY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Miao ZH; Zhang A; He JX
    Eur J Med Chem; 2023 Nov; 259():115709. PubMed ID: 37567056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of PARP inhibitor sensitivity and resistance.
    D'Andrea AD
    DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
    Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
    Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone.
    Kayumov M; Jia L; Pardaev A; Song SS; Mirzaakhmedov S; Ding C; Cheng YJ; Zhang RI; Bao X; Miao ZH; He JX; Zhang A
    Eur J Med Chem; 2022 Oct; 240():114574. PubMed ID: 35785724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression.
    Sun Z; Li L; Zhai B; Hu M; Huang L; Huang S; Ye L; Kong X; Xu J; Bai J; Yan J; Zhou Q; Hu Z; Zhang Y; Jiang Y; Zhang Y; Qiao Z; Zou Y; Xu Y; Zhu Q
    J Med Chem; 2024 Mar; 67(6):4916-4935. PubMed ID: 38477575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.
    Ma L; Chen W; Yang M; Ha S; Xiong S; Zhu J; Xiang H; Luo G
    J Med Chem; 2024 Mar; 67(5):3606-3625. PubMed ID: 38375763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
    Zhang J; Yang C; Tang P; Chen J; Zhang D; Li Y; Yang G; Liu Y; Zhang Y; Wang Y; Liu J; Ouyang L
    J Med Chem; 2022 May; 65(9):6803-6825. PubMed ID: 35442700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective.
    Zhang J; Zhang J; Li H; Chen L; Yao D
    Drug Discov Today; 2023 Jul; 28(7):103607. PubMed ID: 37146962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment.
    Feng B; Yu H; Dong X; Díaz-Holguín A; Antolin AA; Hu H
    J Chem Inf Model; 2024 Oct; 64(19):7725-7742. PubMed ID: 39292752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
    Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
    Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
    Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
    Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
    Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
    Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
    Li P; Zhen Y; Kim C; Liu Z; Hao J; Deng H; Deng H; Zhou M; Wang XD; Qin T; Yu Y
    Sci Adv; 2023 Oct; 9(43):eadg7752. PubMed ID: 37878693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor.
    Liu X; Wei X; Li X; Yu R; Jiang T; Zhao C
    Bioorg Med Chem; 2022 Sep; 69():116892. PubMed ID: 35764034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.